Molecular Targeted Therapies for Hematologic Malignancies

Abstract

Protein kinase inhibition has become a promising strategy for cancer therapy since the successful results obtained with Imatinib in the treatment of Chronic Myeloid Leukemia. Several other compounds that target specific kinases are now in clinical development for myeloid and lymphoid neoplasms. In this chapter we discuss the role of kinase dysregulation in hematologic malignancies and the development of inhibitors for these targets.

Keywords: Protein Kinase Inhibition Abl, PDGFR Inhibitors, Philadelphia chromosome, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloproliferative Disorders, Imatinib, Second Generation Abl Inhibitors, FLT3 Inhibitors, c-KIT Inhibitors, JAK2 inhibitors, Protein Kinase C Inhibitors, Cyclin-dependent Kinase Inhibitors, mTOR inhibitors, Anaplastic Lymphoma Kinase Inhibitors, Limitations of Molecular Targeted Therapies.